Objective: To accurately measure the incidence of gastric cancer among patients with gastric precancerous lesions, and to quantify the excess incidence in comparison with people with normal mucosa on endoscopy and a general population.
Main outcome measures: Incidence of gastric cancer, reported separately for patients with different mucosal changes in biopsy samples. Standardised incidence ratios provided estimation of the relative risk, using the general Swedish population as reference; and hazard ratios were derived from Cox regression modelling for internal comparisons with patients with normal gastric mucosa.
Results: After excluding the first two years of follow-up, 1599 cases of gastric cancer were identified. The annual crude incidence of gastric cancer was 20 × 10 − 5 for those in the normal mucosa group (standardised incidence ratio 1.0), 42 × 10 − 5 for those with minor changes (1.5), 59 × 10 − 5 for the gastritis group (1.8), 100 × 10 − 5 for the atrophic gastritis group (2.8), 129 × 10 − 5 for the intestinal metaplasia group (3.4), and 263 × 10 − 5 for the dysplasia group (6.5). Cox regression modelling confirmed that excess risks increased monotonically with progressive severity of gastric lesions, with the highest hazard ratio of 10.9 (dysplasia vs. normal mucosa, 95% confidence interval 7.7 to 15.4). The increased incidence was stable throughout the follow-up period, and the gaps between cumulative incidence curves grew continuously.
Conclusions: Among patients who undergo gastroscopy with biopsy for clinical indications, approximately 1 in 256 with normal mucosa, 1 in 85 with gastritis, 1 in 50 with atrophic gastritis, 1 in 39 with intestinal metaplasia, and 1 in 19 with dysplasia will develop gastric cancer within 20 years. These numbers, along with cost-benefit analyses, should guide future surveillance policies for these particular patient groups. 2015; 351:h3867. doi: 10.1136/bmj.h3867 Pentoxifylline treatment in severe acute pancreatitis: a pilot, double-blind, placebo-controlled, randomized trial Santhi Swaroop Vege, Tegpal Atwal, Yan Bi, Suresh T. Chari, Magdalen A. Clemens and Felicity T. Enders
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In acute pancreatitis (AP) tumor necrosis factor-α mediates multi-organ failure; in animal models its blockade with pentoxifylline ameliorates AP. The efficacy of pentoxifylline in predicted severe AP (pSAP) was tested in a doubleblinded, randomized, control trial. Twenty-eight patients with pSAP were randomized within 72 h of diagnosis to pentoxifylline or placebo. Baseline characteristics were similar in both groups. The pentoxifylline group had fewer intensive care unit admissions and shorter intensive care unit and hospital stays of longer than 4 days (all P < 0.05). Patients receiving pentoxifylline had no adverse effects. Pentoxifylline within 72 h of pSAP is safe; a larger study of pentoxifylline in AP is needed to confirm efficacy. ClinicalTrials.gov number: NCT01292005. for colorectal cancer (CRC) in patients with long-standing ulcerative colitis (UC).
Methods: Data were obtained from medical records, endoscopy, and histology reports. Primary end points were defined as death, colectomy, withdrawal from surveillance, or censor date (1 January 2013).
Results: A total of 1375 UC patients were followed up for 15 234 patient-years (median, 11 years per patient). CRC was detected in 72 patients (incidence rate (IR), 4.7 per 1000 patient-years). Time-trend analysis revealed that although there was significant decrease in incidence of colectomy performed for dysplasia (linear regression, R = − 0.43; P = 0.007), IR of advanced CRC and interval CRC have steadily decreased over past four decades (Pearson's correlation, − 0.99; P = 0.01 for both trends). The IR of early CRC has increased 2.5-fold in the current decade compared with past decade (χ 2 , P = 0.045); however, its 10-year survival rate was high (79.6%). The IR of dysplasia has similarly increased (χ 2 , P = 0.01), potentially attributable to the recent use of chromoendoscopy that was twice more effective at detecting dysplasia compared with white-light endoscopy (χ 2 , P < 0.001). CRCs were frequently accompanied by synchronous CRC or spatially distinct dysplasia (37.5%). Finally, the risk of CRC was not significantly different between 'indefinite' or low-grade dysplasia (log-rank, P = 0.78).
Conclusions: Colonoscopic surveillance may have a significant role in reducing the risk of advanced and interval CRC while allowing more patients to retain their colon for longer. Given the ongoing risk of early CRC, patients with any grade of dysplasia who are managed endoscopically should be monitored closely with advanced. Methods: This was a cross-sectional study using a USA national pathology database. Patients with oesophageal eosinophilia (≥15 eosinophils per high-power field) comprised the primary case definition and were compared with those with normal oesophageal biopsies. We calculated the crude and adjusted odds of oesophageal eosinophilia by season, as well as by day of the year. Sensitivity analyses were performed using more restrictive case definitions of EoE, and after stratification by climate zone.
Results: Exactly, 14 524 cases with oesophageal eosinophilia and 90 459 normal controls were analysed. The adjusted odds of oesophageal eosinophilia were higher in the late spring and summer months, with the highest odds in July (aOR: 1.13; 95% CI: 1.03-1.24). These findings persisted with increasing levels of oesophageal eosinophilia, as well as across EoE case definitions. Seasonal variation was strongest in temperate and cold climates, and peak diagnosis varied by climate zone.
Conclusions: There is a mild but consistent seasonal variation in the diagnosis of oesophageal eosinophilia and EoE, with cases more frequently diagnosed during summer months. These findings take into account climate and geographic differences, suggesting that aeroallergens may contribute to disease development or flare. Background & aims: Several models have been used to determine prognoses of patients with alcoholic hepatitis. These include static systems (the Maddrey discriminant function; age, bilirubin, international normalized ratio, creatinine [ABIC] score; and model for end-stage liver disease [MELD] score) and dynamic models (the Lille model). We aimed to combine features of all of these models to develop a better method to predict outcomes of patients with alcoholic hepatitis.
Methods:
We collected data from several databases of patients with severe alcoholic hepatitis treated with corticosteroids in France and the United Kingdom to create a model to predict patient survival (derivation cohort, n = 538 patients). We compared the performances of 3 joint-effect models (Maddrey + Lille, MELD + Lille, and ABIC + Lille) to determine which combination had the best prognostic value, based on known patient outcomes. The model was validated using data from trials of the effects of corticosteroids in patients in the United States, France, Korea, and Belgium (n = 604 patients).
Results:
We created a joint-effect model to predict patient survival after 2 and 6 months; in the derivation and validation cohorts it predicted outcome significantly better than either static or dynamic models alone (P < 0.01 for all comparisons). The joint model accurately predicted patient survival regardless of patient risk level. The MELD + Lille combination was better than the Maddrey + Lille or ABIC + Lille combination in predicting patient survival, with Akaike information criterion values of 1305, 1313, and 1312, respectively. For example, based on the MELD + Lille combination model, the predicted 6-month mortality of complete responders with MELD scores of 15-45 (Lille score, 0.16) was 8.5% to 49.7%, compared with 16.4-75.2% for nonresponders (Lille score, 0.45). According to the joint-effect model, for 2 patients with the same baseline MELD score of 21, the patient with a Lille score of 0.45 had a 1.9-fold higher risk of death than the patient with a Lille score of 0.16 (23.7% vs. 12.5%).
Conclusions: By combining results from static and dynamic scoring systems for liver disease, we can better predict outcomes of patients with alcoholic hepatitis, compared with either model alone. This may help patient management and design of clinical trials. Background & aims: The effects of bariatric surgery in patients with nonalcoholic fatty liver disease (NASH) are not well established. We performed a prospective study to determine the biological and clinical effects of bariatric surgery in patients with NASH.
Methods: From May 1994 through May 2013, one hundred and nine morbidly obese patients with biopsy-proven NASH underwent bariatric surgery at the University Hospital of Lille, France (the Lille Bariatric Cohort). Clinical, biological, and histologic data were collected before and 1 year after surgery.
Results
: One year after surgery, NASH had disappeared from 85% of the patients (95% confidence interval [CI]: 75.8-92.2%). Compared with before surgery, patients had significant reductions in mean SD body mass index (BMI, from 49.3 8.2 to 37.4 7) and level of alanine aminotransferase (from 52.1 25.7 IU/l to 25.1 20 IU/l); mean levels of γ-glutamyltransferases were reduced from 51 IU/l before surgery (interquartile range [IQR], 34 − 87 IU/l) to 23 IU/l afterward (IQR, 14 − 33 IU/l) and mean insulin resistance index values were reduced from 3.6 0.5 to 2.9 0.5 (P < 0.01 for each comparison). NASH disappeared from a higher proportion of patients with mild NASH before surgery (94%) than severe NASH (70%) (P < 0.05) according to Brunt score. In histologic analysis, steatosis was detected in 60% of the tissue before surgery (IQR, 40-80%) but only 10% 1 year after surgery (IQR, 2.5-21.3%); the mean nonalcoholic fatty liver disease score was reduced from 5 (IQR, 4 − 5) to 1 (IQR, 1 − 2) (each P < 0.001). Hepatocellular ballooning was reduced in 84.2% of samples (n = 69; 95% CI: 74.4 − 91.3) and lobular inflammation in 67.1% (n = 55; 95% CI: 55.8 − 77.1). According to Metavir scores, fibrosis was reduced in 33.8% of patients (95% CI: 23.6-45.2%).
Patients whose NASH persisted 1 year after surgery (n = 12) had lost significantly less weight (change in BMI, 9.1 1.5) than those without NASH (change in BMI, 12.3 0.6) (P = 0.005). Patients who underwent laparoscopic gastric banding lost less weight (change in BMI, 6.4 0.7) than those who underwent gastric bypass (change in BMI, 14.0 0.5) (P < 0.0001), and a higher proportion had persistent NASH (30.4% vs. 7.6% of those with gastric bypass; P = 0.015).
Conclusions: Bariatric surgery induced the disappearance of NASH from nearly 85% of patients and reduced the pathologic features of the disease after 1 year of follow-up. It could be a therapeutic option for appropriate morbidly obese patients with NASH who do not respond to lifestyle modifications. More studies are needed to determine the long-term effects of bariatric surgery in morbidly obese patients with NASH. The efficacy and safety of maternal tenofovir disoproxil fumarate (TDF) in reducing mother-to-infant hepatitis B virus (HBV) transmissions is not clearly understood. We conducted a prospective, multicenter trial and enrolled 118 hepatitis B surface antigen (HBsAg)-and hepatitis B e antigen-positive pregnant women with HBV DNA ≥ 7.5 log10 IU/ml. The mothers received no medication (control group, n = 56, HBV DNA 8.22 0.39 log10 IU/ml) or TDF 300 mg daily (TDF group, n = 62, HBV DNA 8.18 0.47 log10 IU/ml) from 30-32 weeks of gestation until 1 month postpartum. Primary outcome was infant HBsAg at 6 months old. At delivery, the TDF group had lower maternal HBV DNA levels (4.29 0.93 vs. 8.10 0.56 log10 IU/ml, P < 0.0001). Of the 121/123 newborns, the TDF group had lower rates of HBV DNA positivity at birth (6.15% vs. 31.48%, P = 0.0003) and HBsAg positivity at 6 months old (1.54% vs. 10.71%, P = 0.0481). Multivariate analysis revealed that the TDF group had lower risk (odds ratio = 0.10, P = 0.0434) and amniocentesis was associated with higher risk (odds ratio 6.82, P = 0.0220) of infant HBsAg positivity. The TDF group had less incidence of maternal alanine aminotransferase (ALT) levels above two times the upper limit of normal for ≥ 3 months (3.23% vs. 14.29%, P = 0.0455), a lesser extent of postpartum elevations of ALT (P = 0.007), and a lower rate of ALT over five times the upper limit of normal (1.64% vs. 14.29%, P = 0.0135) at 2 months postpartum. Maternal creatinine and creatinine kinase levels, rates of congenital anomaly, premature birth, and growth parameters in infants were comparable in both groups. At 12 months, one TDF-group child newly developed HBsAg positivity, presumably due to postnatal infection and inefficient humoral responses to vaccines. Conclusions: Treatment with TDF for highly viremic mothers decreased infant HBV DNA at birth and infant HBsAg positivity at 6 months and ameliorated maternal ALT elevations.
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